Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Seeks Public Input on Drug Trial Data Protection Measures

Fineline Cube Mar 20, 2025

On March 19, 2025, China’s National Medical Products Administration (NMPA) released draft measures and procedures...

Company Medical Device

Telix Pharmaceuticals Gains Brazilian Approval for Prostate Cancer Diagnostic Agent TLX591-CDx

Fineline Cube Mar 19, 2025

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) announced receiving clearance from the Brazilian Health Regulatory Agency...

Company Deals Hospital

Distinct Healthcare Files for Hong Kong IPO to Expand Integrated Medical Services

Fineline Cube Mar 19, 2025

Shenzhen-based Distinct Healthcare Holdings Limited, a comprehensive medical service provider with integrated online and offline...

Company

Pfizer Restructures China Operations to Boost Growth and Innovation

Fineline Cube Mar 19, 2025

US-based pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced a significant leadership and organizational restructuring in...

Policy / Regulatory

CDE’s 2024 Annual Drug Review Report Shows Continued Growth in Regulatory Filings

Fineline Cube Mar 19, 2025

The Center for Drug Evaluation (CDE) released its 2024 annual drug review report, highlighting continued...

Company

Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production

Fineline Cube Mar 19, 2025

China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in...

Company Deals

GE Healthcare and NVIDIA Expand Partnership to Advance Autonomous X-ray and Ultrasound Technologies

Fineline Cube Mar 19, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced an...

Company Drug

Tonghua Dongbao Initiates Phase III Trial for Insulin Degludec, Liraglutide Combo in Type 2 Diabetes

Fineline Cube Mar 19, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has initiated a Phase III clinical study for its...

Company Deals

Formosa Pharmaceuticals Inks Licensing Pact with Cipla for APP13007 in 11 Countries

Fineline Cube Mar 19, 2025

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with India-headquartered Cipla Limited (BOM: 500087,...

Company Drug

AccurEdit Therapeutics Receives FDA Orphan Drug Designation for ATTR Treatment

Fineline Cube Mar 19, 2025

China-based AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Orphan Drug Designation (ODD) from the US...

Company Drug

Johnson & Johnson’s Nipocalimab Receives FDA Fast Track Designation for Sjögren’s Disease

Fineline Cube Mar 19, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) announced receiving Fast Track designation (FTD) from...

Company

Medbanks Reports 2024 Financial Results Amid Business Reorganization

Fineline Cube Mar 19, 2025

Sipai Health Technology Co., Ltd (HKG: 0314), known as Medbanks, released its 2024 financial report....

Company Drug

AstraZeneca’s Imfinzi Approved in EU for Limited-Stage Small Cell Lung Cancer

Fineline Cube Mar 19, 2025

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has received approval from the European Union (EU) for...

Company Drug

HutchMed and Innovent Announce Positive Results for Fruquintinib and Sintilimab in Renal Cell Carcinoma Trial

Fineline Cube Mar 19, 2025

Chinese companies HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...

Company Deals

Convalife and XLement Launch AI-Powered Joint Lab for Drug Development Innovation

Fineline Cube Mar 19, 2025

On March 19, 2025, Convalife Pharmaceuticals and XLement announced a strategic partnership to establish the...

Company

Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform

Fineline Cube Mar 19, 2025

Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital,...

Company Medical Device

GE Healthcare Launches AltiX AI.i Edition for Enhanced Cardiac Procedures

Fineline Cube Mar 18, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the...

Company

WuXi AppTec Reports Steady Revenue Growth Amid Diversified Business Expansion

Fineline Cube Mar 18, 2025

China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) released its 2024 financial...

Company Deals

Eisai Launches JPY16 Billion Tender for EcoNaviSta to Expand Dementia Care Ecosystem

Fineline Cube Mar 18, 2025

Japan-based Eisai Co., Ltd (TYO: 4523) announced a tender offer valued at JPY16 billion (USD107...

Company Drug

Bayer’s Kerendia Gets FDA Priority Review for Heart Failure with Preserved Ejection Fraction

Fineline Cube Mar 18, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced that a supplementary New Drug Application (sNDA) for...

Posts pagination

1 … 185 186 187 … 657

Recent updates

  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.